EUROPRISE - European Vaccine and Microbicides Enterprise (FP6-LIFESCIHEALTH) (2007-01-01 - 2011-12-31) (»add to infobox)

Robin SHATTOCK, Britta WAHREN, Rino RAPPUOLI, Donata MEDAGLINI, Aldo TAGLIABUE, Gerald VOSS, Gabriela STIEGLER, Charles KELLY, Giuseppe SCALA, Klaus ÜBERLA, Harvey HOLMES, Robin A. WEISS, Frances GOTCH, Vicky JESPERS, Sheena MCCORMACK, Gabriella SCARLATTI, Roger LE GRAND, Bernard VERRIER, Charles LACEY, Quentin SATTENTAU, Paolo LA COLLA, Christiane STAHL-HENNIG, Eva Maria FENYO, Frederic TANGY, Hanneke SCHUITEMAKER, Jose ALCAMI, Geert LEROUX-ROELS, Donato ZIPETO, Stephen NORLEY, Eduard Vladimirovich KARAMOV, Kopek NIHLMARK, Nikos DEDES, Christiane MOOG

ST GEORGE'S HOSPITAL MEDICAL SCHOOL (UKI11 - Inner London - West) (Great Britain), KAROLINSKA INSTITUTET (SE010 - Stockholms län) (Sweden), NOVARTIS VACCINES AND DIAGNOSTICS SRL (ITE19 - Siena) (Italy), UNIVERSITA DEGLI STUDI DI SIENA (ITE19 - Siena) (Italy), ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRL-ALTA SRL (ITE19 - Siena) (Italy), GLAXOSMITHKLINE BIOLOGICALS SA (BE310 - Arr. Nivelles) (Belgium), POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSHUNGS GMBH (AT130 - Wien) (Austria), KING'S COLLEGE LONDON (UKI11 - Inner London - West) (Great Britain), UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II (ITF33 - Napoli) (Italy), RUHR-UNIVERSITAET BOCHUM (DEA51 - Bochum, Kreisfreie Stadt) (Germany), NATIONAL BIOLOGICAL STANDARDS BOARD (UKH23 - Hertfordshire) (Great Britain), UNIVERSITY COLLEGE LONDON (UKI11 - Inner London - West) (Great Britain), IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (UKI11 - Inner London - West) (Great Britain), PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE (BE211 - Arr. Antwerpen) (Belgium), MEDICAL RESEARCH COUNCIL (UKI11 - Inner London - West) (Great Britain), FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR (ITC45 - Milano) (Italy), COMMISSARIAT A L'ENERGIE ATOMIQUE (CEA) (FR101 - Paris) (France), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR716 - Rhône) (France), UNIVERSITY OF YORK (UKE21 - York) (Great Britain), THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (UKJ14 - Oxfordshire) (Great Britain), UNIVERSITA DEGLI STUDI DI CAGLIARI (ITG2 - Sardegna) (Italy), DEUTSCHES PRIMATENZENTRUM GMBH (DE915 - Göttingen) (Germany), LUNDS UNIVERSITET (SE044 - Skåne län) (Sweden), INSTITUT PASTEUR (FR101 - Paris) (France), STICHTING SANQUIN BLOEDVOORZIENING (NL326 - Groot-Amsterdam) (Netherlands), INSTITUTO DE SALUD CARLOS III (ES300 - Madrid) (Spain), UNIVERSITEIT GENT (BE234 - Arr. Gent) (Belgium), UNIVERSITA DEGLI STUDI DI VERONA (ITD31 - Verona) (Italy), ROBERT KOCH-INSTITUT (DE300 - Berlin) (Germany), IVANOVSKY INSTITUTE OF VIROLOGY,RUSSIAN ACADEMY OF MEDICAL SCIENCE (NoRegion - NoRegion) (Russia), MABTECH AB (SE010 - Stockholms län) (Sweden), EUROPEAN AIDS TREATMENT GROUP EV (DEA11 - Düsseldorf, Kreisfreie Stadt) (Germany), UNIVERSITE LOUIS PASTEUR (FR421 - Bas-Rhin) (France)

The successful development of preventative strategies against HIV-1 (microbicides, vaccines or their combined effects) would provide a pivotal turning point in global efforts to combat the pandemic spread of AIDS providing an incalculable impact on solving societal problems associated with this disease. The principal aim of this proposal is to bring together EU scientists from both microbicide and vaccine fields to embrace a coordinated approach to HIV-1 prevention research. Partners in the EUROPRISE consortium represent 14 projects funded by the European Commission in the sixth Framework as well as one project funded by the Gates Foundation. These projects involve 132 institutions from 22 countries. In this respect, EUROPRISE is the first organisation, both in Europe and internationally to deliberately bring these groups together in a truly integrated fashion. EUROPRISE will promote an integrated program of research, coordinating a wide portfolio of activities encompassing the whole pipeline of vaccine and microbicide development from early discovery through to early clinical trials. This unique approach places the Network at the international forefront of understanding the interface between these two technologies, pursing a critical path to the development of effective HIV-1 prevention strategies.

PERSONS (33/33)

RELATED NAVIGATION AREA(S) (3/3)